It is reasonable to use ticagrelor in preference to clop- idogrel for maintenance P2Y12 treatment in patients with NSTE-ACS who undergo an early invasive or (Level of Evidence: B) 3. It is reasonable to choose prasugrel over clopidogrel for maintenance P2Y12 treatment in patients with NSTE-ACS who undergo PCI who are not at high risk for bleeding complications.302,303 (Level of Evidence: B) 4. If the risk of morbidity from bleeding outweighs the anticipated benefit of a recommended duration of inhibitor therapy after stent implantation, ear- lier discontinuation (eg, <12 months) of P2Y12 inhibi- tor therapy is reasonable.330 (Level of Evidence: C) Class IIb 1. Continuation of DAPT beyond 12 months may be considered in patients undergoing stent implanta- tion. (Level of Evidence: C) 6.2.2. Combined Oral Anticoagulant Therapy and Antiplatelet Therapy in Patients With NSTE-ACS Class I 1. The duration of triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y12 recep- tor inhibitor in patients with NSTE-ACS should be minimized to the extent possible to limit the risk of bleeding. (Level of Evidence: C) 2. Proton pump inhibitors should be prescribed in pa- tients with NSTE-ACS with a history of gastroin- testinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a (Level of Evidence: C) Class IIa 1. Proton pump inhibitor use is reasonable in patients with NSTE-ACS without a known history of gastro- intestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a (Level of Evidence: C) Class IIb 1. Targeting oral anticoagulant therapy to a lower in- ternational normalized ratio (INR) (eg, 2.0 to 2.5) may be reasonable in patients with NSTE-ACS man- aged with aspirin and a P2Y12 inhibitor. 